
213. The Decline And Fall Of The London Stock Exchange
The Rest Is Money
00:00
AstraZeneca's US Listing and Stamp Duty Risk
Robert explains AstraZeneca's US listing move, the UK depository receipt change, and its potential £200m stamp duty cost.
Transcript
Play full episode